Executive summary The 2024 update of the Lancet Commission on dementia provides new
hopeful evidence about dementia prevention, intervention, and care. As people live longer …

Background Development of in vivo biomarkers has shifted the diagnosis of Alzheimer's
disease (AD) from the later dementia stages of disease towards the earlier stages and has …

Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …

Alzheimer's disease (AD) is characterized by the spread of tau pathology throughout the
cerebral cortex. This spreading pattern was thought to be fairly consistent across individuals …

Gold-standard diagnosis of Alzheimer's disease (AD) relies on histopathological staging
systems. Using the topographical information from [18F] MK6240 tau positron-emission …

Most patients with Alzheimer's disease present with amnestic problems; however, a
substantial proportion, over-represented in young-onset cases, have atypical phenotypes …

Early-onset Alzheimer's disease (EOAD) is a rare but particularly devastating form of AD.
Though notable for its high degree of clinical heterogeneity, EOAD is defined by the same …

β-Amyloid plaques and tau-containing neurofibrillary tangles are the two neuropathological
hallmarks of Alzheimer's disease (AD) and are thought to play crucial roles in a …

The history of Alzheimer's disease (AD) started in 1907, but we needed to wait until the end
of the century to identify the components of pathological hallmarks and genetic subtypes and …

The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease
emphasises the need for consensus recommendations on the rational use of biomarkers to …